Medical Marijuana, Inc. Subsidiary Kannaway Launches in Hong Kong

Rhea-AI Summary

Medical Marijuana, Inc. (OTC: MJNA) announced that its subsidiary, Kannaway®, has expanded operations into Hong Kong following success in Japan. CEO Blake Schroeder highlighted the growing demand for high-quality cannabidiol (CBD) products as interest in hemp-derived CBD increases in the region. Kannaway® plans to host regional events to educate Brand Ambassadors about wellness benefits and financial opportunities. The company continues to be a pioneer in the cannabis industry, having developed a robust international market.

Positive

• Expansion into Hong Kong indicates growth potential in Asian markets.
• Successful past operations in Japan can drive confidence in the Hong Kong market.
• Focus on education for Brand Ambassadors may enhance sales efforts.

Negative

• None.

SAN DIEGO, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company’s subsidiary Kannaway® has launched its operations in Hong Kong.

​​"Our first Asian expansion has been a fantastic success in Japan and we now look forward to bringing our high-quality cannabidiol (CBD) products to Hong Kong as well," Kannaway® CEO Blake Schroeder said. "Hemp has a long history in the region and, according to MJBizDaily, China is the world’s largest hemp producer. Now, with the global popularity of CBD on the rise, we’re seeing the citizens of Hong Kong who want to go back to their roots use hemp-derived CBD.”

Kannaway® will be hosting regional events to educate current and potential Brand Ambassadors on the many potential wellness benefits and financial opportunities of hemp-derived CBD oil.

About Kannaway®
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.

About Medical Marijuana, Inc.

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:
Kathryn Brown
Account Director
CMW Media
P. 858-264-6600
kathryn@cmwmedia.com
www.cmwmedia.com

Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com

FAQ

What is the significance of Medical Marijuana, Inc.'s expansion into Hong Kong?

The expansion marks Medical Marijuana, Inc.'s first entry into the Asian market, following the success of its subsidiary in Japan, indicating potential growth in a new region.

What products will Kannaway® offer in Hong Kong?

Kannaway® will provide its high-quality cannabidiol (CBD) products tailored to the growing demand in Hong Kong.

What strategy is Kannaway® using to promote its products in Hong Kong?

Kannaway® plans to host regional events aimed at educating potential Brand Ambassadors about the wellness benefits of hemp-derived CBD oil and financial opportunities.

How does Medical Marijuana, Inc. view the hemp market in Asia?

The company sees significant potential in the Asian market, especially with the historical context of hemp use in regions like Hong Kong and the increasing global popularity of CBD.